PPE and Air Hygiene for Flu Prevention
(EMIT-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how personal protective equipment (PPE) can prevent the airborne spread of the flu. Participants are divided into groups: one uses PPE to determine its effectiveness in stopping flu transmission, while the other does not. The trial seeks individuals who have recently had the flu or have not had it but are willing to use PPE for the study. Ideal candidates do not smoke or have complex health issues requiring ongoing medical treatment. As an unphased trial, this study allows participants to contribute to important research on flu prevention.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications. However, if you are on medications that suppress the immune system or treat significant medical conditions like respiratory or cardiovascular diseases, you may not be eligible to participate.
What prior data suggests that personal protective equipment (PPE) is safe for flu prevention?
Research has shown that personal protective equipment (PPE), such as masks, gloves, and face shields, is generally safe to use. Designed to protect against germs, these items are commonly used in healthcare settings. Studies have found that PPE, when used correctly, can reduce the risk of infection without harming the user.
No major reports of problems from wearing PPE have emerged. However, proper use is crucial for effectiveness. For instance, face masks should fit snugly, and hands should be clean when putting on gloves. This ensures that PPE remains a safe and effective method for preventing flu and other infections.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores how personal protective equipment (PPE) might prevent the spread of influenza. Unlike typical flu prevention methods, such as vaccines and antiviral medications, this approach focuses on using PPE to block airborne transmission. This trial could reveal how effective PPE is as a preventive measure, potentially offering a simple and accessible way to reduce flu transmission, especially in settings where vaccines aren't available or effective.
What evidence suggests that personal protective equipment is effective for flu prevention?
This trial will compare the use of personal protective equipment (PPE) with no intervention for flu prevention. Studies have shown that face masks can greatly protect healthcare workers from infections. However, research on their effectiveness for the general public remains less clear. Some reviews have found no strong evidence that face masks reduce flu infections among everyday people. Gloves, although used in some situations, have not shown a clear effect on stopping respiratory viruses like the flu. Overall, PPE might help but does not guarantee flu prevention. It is best used as part of a broader prevention strategy.26789
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 18-49 who have recently contracted the flu. Participants must understand the study, stay in a research unit for about 5 days, and attend follow-ups. Pregnant or breastfeeding women, smokers, those with severe allergies to medicines, immunosuppressed individuals or those on certain medications cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are exposed to controlled human influenza virus infection and interventions to reduce airborne transmission are implemented
Follow-up
Participants are monitored for serological, symptomatic, and viral confirmation of influenza infection
What Are the Treatments Tested in This Trial?
Interventions
- No Intervention
- Personal Protective Equipment (PPE)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor
University of Maryland, College Park
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator